Short Interest in Cel-Sci Corporation (NYSEAMERICAN:CVM) Declines By 64.0%

Cel-Sci Corporation (NYSEAMERICAN:CVM) saw a large decline in short interest in May. As of May 15th, there was short interest totaling 255,031 shares, a decline of 64.0% from the April 30th total of 708,414 shares. Approximately 3.3% of the company’s stock are sold short. Based on an average daily volume of 1,289,720 shares, the short-interest ratio is presently 0.2 days.

Institutional Trading of Cel-Sci

Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its position in Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock worth $94,000 after buying an additional 39,190 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Cel-Sci by 59.7% during the 3rd quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock valued at $2,692,000 after buying an additional 109,352 shares in the last quarter. MAI Capital Management grew its stake in shares of Cel-Sci by 18.4% during the 3rd quarter. MAI Capital Management now owns 76,861 shares of the company’s stock valued at $707,000 after acquiring an additional 11,928 shares during the period. US Bancorp DE bought a new position in shares of Cel-Sci during the 3rd quarter valued at approximately $80,000. Finally, HighTower Advisors LLC purchased a new stake in Cel-Sci in the 4th quarter worth approximately $53,000. 12.08% of the stock is currently owned by institutional investors.

Cel-Sci Stock Up 4.1%

NYSEAMERICAN:CVM traded up $0.06 on Friday, reaching $1.54. 188,823 shares of the stock traded hands, compared to its average volume of 916,515. The company has a current ratio of 0.60, a quick ratio of 0.54 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $13.07 million, a price-to-earnings ratio of -0.16 and a beta of 0.70. Cel-Sci has a 12 month low of $0.89 and a 12 month high of $13.48. The company’s fifty day simple moving average is $2.85 and its 200 day simple moving average is $4.51.

Cel-Sci (NYSEAMERICAN:CVM) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.67) EPS for the quarter.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.